Status:
COMPLETED
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
Lead Sponsor:
The Rogosin Institute
Conditions:
Intraabdominal Cancers (Various Types)
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatm...
Detailed Description
Cancer in its various forms continues to be a major U.S. health problem, accounting for 550,000 deaths a year, as well as much disability and suffering. Treatment for cancer has traditionally consiste...
Eligibility Criteria
Inclusion
- End-stage, treatment resistant epithelial-derived cancer (carcinoma) arising originally within the abdominal cavity with expected minimum six-month survival
Exclusion
- Multiple intraabdominal metastases or carcinomatosis or other medical conditions indicating that the procedure would be of too high a risk for the individual
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00283075
Start Date
January 1 2005
End Date
February 1 2015
Last Update
January 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NewYork Presbyterian Weill Cornell Medical Center
New York, New York, United States, 10021